These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19451444)

  • 1. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
    Angelov L; Doolittle ND; Kraemer DF; Siegal T; Barnett GH; Peereboom DM; Stevens G; McGregor J; Jahnke K; Lacy CA; Hedrick NA; Shalom E; Ference S; Bell S; Sorenson L; Tyson RM; Haluska M; Neuwelt EA
    J Clin Oncol; 2009 Jul; 27(21):3503-9. PubMed ID: 19451444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
    Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
    Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
    Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
    Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
    Yu J; Du H; Ye X; Zhang L; Xiao H
    Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption.
    Vicuna-Kojchen J; Frenkel S; Siegal T; Shalom E; Chowers I; Pe'er J
    Br J Ophthalmol; 2008 Feb; 92(2):231-5. PubMed ID: 18227203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
    Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
    Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
    Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
    Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
    J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
    Kuitunen H; Tokola S; Siniluoto T; Isokangas M; Sonkajärvi E; Alahuhta S; Turpeenniemi-Hujanen T; Jantunen E; Nousiainen T; Vasala K; Kuittinen O
    J Neurooncol; 2017 Jan; 131(2):293-300. PubMed ID: 27752883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
    Korfel A; Thiel E; Martus P; Möhle R; Griesinger F; Rauch M; Röth A; Hertenstein B; Fischer T; Hundsberger T; Mergenthaler HG; Junghanß C; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Roth P; Bamberg M; Pietsch T; Weller M
    Neurology; 2015 Mar; 84(12):1242-8. PubMed ID: 25716362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
    Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
    Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate re-challenge for recurrent primary central nervous system lymphoma.
    Pentsova E; Deangelis LM; Omuro A
    J Neurooncol; 2014 Mar; 117(1):161-5. PubMed ID: 24481997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
    Rubenstein JL; Hsi ED; Johnson JL; Jung SH; Nakashima MO; Grant B; Cheson BD; Kaplan LD
    J Clin Oncol; 2013 Sep; 31(25):3061-8. PubMed ID: 23569323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
    Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
    Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
    Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
    Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.